Paradigmenwechsel in der Glukosekontrolle: Urin-, Blut-, interstitielle Glukosemessung

Die selbstständige Blutzuckerkontrolle ist für viele Patienten mit Diabetes mellitus heute ein fester Bestandteil des Krankheitsmanagements. Eine kontinuierliche interstitielle Glukosemessung ermöglicht eine weitere Verbesserung der Dosisanpassung bei Patienten unter intensivierter konventioneller Insulinbehandlung und bei Patienten mit Insulinpumpen.

Abstract

Today, self-measurement of glucose concentrations represents an integral part in disease management for many patients with diabetes mellitus. Starting with urine glucose test stripes about 50 years ago, patients were enabled to perform measurements of glucose control by their own. Proceeding from urine glucose measurements to capillary blood glucose in the 1960ies provided totally new opportunities and created the basis for modern intensified insulin treatment with an adaptation of insulin dosages according to actual blood glucose concentrations. Today, we are moving from punctual capillary blood glucose measurements to continuous measurement of glucose concentrations in the interstitial fluid. Again, opening a new century of glucose control for patients with diabetes mellitus. The opportunity of continuous glucose monitoring allows further improvement in insulin dose adaptation in patients on intensified conventional insulin treatment and those on insulin pumps. Connecting continuous glucose sensors with insulin pumps allow for continuous adaptation of insulin supply based on actual glucose readings and might pave the way to an artificial pancreas. With all these progress in glucose sensing technologies, it is still essential to teach the patients about the meaning of their glucose readings, and to draw adequate therapeutical conclusions.

Kernaussagen

• Messungen zur Glukosekontrolle selbst durchzuführen ist für viele Patienten mit Diabetes mellitus ein fester Bestandteil des Krankheitsmanagements.

• Der Übergang von der Uringlukosemessung zur Kapillarblutglukose in den 1960er-Jahren schuf die Grundlage für die moderne intensivierte Insulinbehandlung durch die Anpassung der Insulindosierung an die tatsächlichen Blutzuckerkonzentration.

• Heute gehen wir von der punktuellen kapillaren Blutglukosemessung zur kontinuierlichen Messung der Glukosekonzentration in der interstitiellen Flüssigkeit über.

• Die Möglichkeit der kontinuierlichen Glukosemessung erlaubt eine weitere Verbesserung der Anpassung der Insulindosis bei Patienten, die eine intensivierte konventionelle Insulinbehandlung erhalten oder eine Insulinpumpe tragen.

• Die Kopplung kontinuierlicher Glukosesensoren an Insulinpumpen ermöglicht eine kontinuierliche Anpassung der Insulinzufuhr auf der Grundlage der aktuellen Glukosemesswerte und könnte den Weg zu einer künstlichen Bauchspeicheldrüse ebnen.

• Bei allen technologischen Fortschritten ist es nach wie vor unerlässlich, die Patienten über die Bedeutung ihrer Glukosemesswerte aufzuklären und angemessene therapeutische Schlussfolgerungen zu ziehen.

Schlüsselwörter

Glukosemessung - Uringlukose - Blutglukose - interstitielle Glukose - Glukosekontrollierte Insulintherapie

Keywords

glucose measurement - urinary glucose - blood glucose - interstitial glucose - glucose-controlled insulin treatment

Publication History

Article published online:
09 June 2022

• Literatur

• 1 Durán A, Martín P, Runkle I. et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. Journal of diabetes 2010; 2: 203-211 DOI: 10.1111/j.1753-0407.2010.00081.x. (PMID: 20923485)
• 2 Wallace TM, Meston NM, Gardner SG. et al. The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. Diabet Med 2001; 18: 640-645 DOI: 10.1046/j.1464-5491.2001.00550.x. (PMID: 11553201)
• 3 Erbach M, Freckmann G, Hinzmann R. et al. Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge. J Diabet Sci Technol 2016; 10: 1161-1168 DOI: 10.1177/1932296816641433. (PMID: 27044519)
• 4 Schmid C, Haug C, Heinemann L. et al. System accuracy of blood glucose monitoring systems: impact of use by patients and ambient conditions. Diabet Technol Ther 2013; 15: 889-896 DOI: 10.1089/dia.2013.0047. (PMID: 23883407)
• 5 Bilen H, Kilicaslan A, Akcay G. et al. Performance of glucose dehydrogenase (GDH) based and glucose oxidase (GOX) based blood glucose meter systems at moderately high altitude. J Med Eng Technol 2007; 31: 152-156 DOI: 10.1080/03091900600861590. (PMID: 17365439)
• 6 Solnica B, Skupien J, Kusnierz-Cabala B. et al. The effect of hematocrit on the results of measurements using glucose meters based on different techniques. Clin Chem Lab Med 2011; 50: 361-365 DOI: 10.1515/cclm.2011.770. (PMID: 22047145)
• 7 Demircik F, Ramljak S, Hermanns I. et al. Evaluation of hematocrit interference with MyStar extra and seven competitive devices. J Diabet Sci Technol 2015; 9: 262-267 DOI: 10.1177/1932296814565790.
• 8 Heinemann L. Quality of glucose measurement with blood glucose meters at the point-of-care: relevance of interfering factors. Diabet Technol Ther 2010; 12: 847-857 DOI: 10.1089/dia.2010.0076.
• 9 Tang Z, Du X, Louie RF. et al. Effects of drugs on glucose measurements with handheld glucose meters and a portable glucose analyzer. Am J Clin Pathol 2000; 113: 75-86 DOI: 10.1309/qaw1-x5xw-bvrq-5lkq. (PMID: 10631860)
• 10 Battelino T, Danne T, Bergenstal RM. et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabet Care 2019; 42: 1593-1603 DOI: 10.2337/dci19-0028.
• 11 Lu J, Wang C, Shen Y. et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabet Care 2021; 44: 549-555 DOI: 10.2337/dc20-1862.
• 12 Langendam M, Luijf YM, Hooft L. et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012; 1: Cd008101 DOI: 10.1002/14651858.CD008101.pub2. (PMID: 22258980)
• 13 Ida S, Kaneko R, Murata K. Utility of Real-Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. J Diabet Res 2019; 2019: 4684815 DOI: 10.1155/2019/4684815.
• 14 Pratley RE, Kanapka LG, Rickels MR. et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2020; 323: 2397-2406 DOI: 10.1001/jama.2020.6928. (PMID: 32543682)
• 15 Charleer S, Mathieu C, Nobels F. et al. Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. J Clin Endocrinol Metab 2018; 103: 1224-1232 DOI: 10.1210/jc.2017-02498. (PMID: 29342264)
• 16 Feig DS, Donovan LE, Corcoy R. et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017; 390: 2347-2359 DOI: 10.1016/s0140-6736(17)32400-5. (PMID: 28923465)
• 17 Weisman A, Bai JW, Cardinez M. et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabet Endocrinol 2017; 5: 501-512 DOI: 10.1016/s2213-8587(17)30167-5.